AbCellera Biologics (ABCL) Change in Cash (2020 - 2025)
AbCellera Biologics' Change in Cash history spans 6 years, with the latest figure at $44.8 million for Q4 2025.
- For the quarter ending Q4 2025, Change in Cash rose 50.92% year-over-year to $44.8 million, compared with a TTM value of -$28.4 million through Dec 2025, down 223.3%, and an annual FY2025 reading of -$28.4 million, down 223.3% over the prior year.
- Change in Cash for Q4 2025 was $44.8 million at AbCellera Biologics, up from -$9.3 million in the prior quarter.
- The five-year high for Change in Cash was $245.8 million in Q2 2022, with the low at -$417.4 million in Q3 2022.
- Average Change in Cash over 5 years is -$21.9 million, with a median of -$8.3 million recorded in 2023.
- Biggest YoY gain for Change in Cash was 341.35% in 2021; the steepest drop was 1146.27% in 2021.
- Tracing ABCL's Change in Cash over 5 years: stood at -$16.6 million in 2021, then surged by 187.98% to $14.6 million in 2022, then tumbled by 368.51% to -$39.1 million in 2023, then skyrocketed by 175.92% to $29.7 million in 2024, then surged by 50.92% to $44.8 million in 2025.
- Per Business Quant, the three most recent readings for ABCL's Change in Cash are $44.8 million (Q4 2025), -$9.3 million (Q3 2025), and -$66.8 million (Q2 2025).